Pharma BD Deal Intelligence
Cubist Pharmaceuticals to acquire Trius Therapeutics for $13.50 per share, approximately $707 million, adding the highly complementary late-stage antibiotic…
Trius Therapeutics tender-offer communication describing the Cubist acquisition terms of $13.50 per share in cash plus a contingent value right for up to an…
Tedizolid is 4-to-16-fold more potent against staphylococci and enterococci than linezolid, was approved under the GAIN Act with five extra years of market…
Source summaries from our enrichment pipeline; follow links for originals.
All 7 sources with sentiment breakdown →
Cubist to acquire Trius at $13.50/share cash (~$707M fully diluted); added late-stage tedizolid antibiotic plus preclinical antibiotic programs to anti-infective portfolio.
Assessment window: 5yr post-close.
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Cubist Pharmaceuticals, Inc. / Trius Therapeutics Inc. (this deal) | 2013 | $707M | 44 |
| Cubist Pharmaceuticals, Inc. / Calixa Therapeutics, Inc. | 2009 | $402M | 52 |
| Cubist Pharmaceuticals, Inc. / Adolor Corporation | 2011 | $415M | 49 |
| Cubist Pharmaceuticals, Inc. / Optimer Pharmaceuticals, Inc. | 2013 | $801M | 45 |
| Pfizer Inc. / BioNTech SE | 2020 | $748M | 100 |
| Gilead Sciences Inc. / Pharmasset Inc. | 2011 | $11.2B | 98 |
| Abbott Laboratories / Alere Inc. | 2016 | $5.8B | 95 |
← Browse all deals · How we score deals
More: 2013 deals · Cubist Pharmaceuticals, Inc. deals · Infectious Disease deals